It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Dynamic regulation of gene expression is fundamental for cellular adaptation to exogenous stressors. P-TEFb-mediated pause-release of RNA polymerase II (Pol II) is a conserved regulatory mechanism for synchronous transcriptional induction in response to heat shock, but this pro-survival role has not been examined in the applied context of cancer therapy. Using model systems of pediatric high-grade glioma, we show that rapid genome-wide reorganization of active chromatin facilitates P-TEFb-mediated nascent transcriptional induction within hours of exposure to therapeutic ionizing radiation. Concurrent inhibition of P-TEFb disrupts this chromatin reorganization and blunts transcriptional induction, abrogating key adaptive programs such as DNA damage repair and cell cycle regulation. This combination demonstrates a potent, synergistic therapeutic potential agnostic of glioma subtype, leading to a marked induction of tumor cell apoptosis and prolongation of xenograft survival. These studies reveal a central role for P-TEFb underpinning the early adaptive response to radiotherapy, opening avenues for combinatorial treatment in these lethal malignancies.
The mechanisms underlying adaptive response to the stress elicited by radiotherapy in glioma cells remains unclear. Here, the authors show that therapeutic ionizing radiation induces rapid genome-wide chromatin reorganization to facilitate P-TEFb-mediated nascent transcriptional induction, which could be targeted to sensitize radiotherapy response in glioma.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Kargar, Soudabeh 4 ; Serkova, Natalie J. 5 ; Foreman, Nicholas K. 6 ; Venkataraman, Sujatha 1 ; Dowell, Robin 7
; Vibhakar, Rajeev 6 ; Dahl, Nathan A. 8
1 University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)
2 University of Colorado School of Medicine, Department of Biomedical Informatics, Aurora, USA (GRID:grid.499234.1) (ISNI:0000 0004 0433 9255); University of Colorado School of Medicine, University of Colorado Cancer Center, Aurora, USA (GRID:grid.499234.1) (ISNI:0000 0004 0433 9255)
3 University of Colorado School of Medicine, Department of Radiation Oncology, Aurora, USA (GRID:grid.499234.1) (ISNI:0000 0004 0433 9255)
4 University of Colorado School of Medicine, University of Colorado Cancer Center, Aurora, USA (GRID:grid.499234.1) (ISNI:0000 0004 0433 9255)
5 University of Colorado School of Medicine, Department of Radiology, Aurora, USA (GRID:grid.499234.1) (ISNI:0000 0004 0433 9255)
6 University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X); Children’s Hospital Colorado, Center for Cancer and Blood Disorders, Aurora, USA (GRID:grid.413957.d) (ISNI:0000 0001 0690 7621); University of Colorado School of Medicine, Department of Neurosurgery, Aurora, USA (GRID:grid.499234.1) (ISNI:0000 0004 0433 9255)
7 University of Colorado, Department of Molecular, Cellular, and Developmental Biology, Boulder, USA (GRID:grid.266190.a) (ISNI:0000 0000 9621 4564); University of Colorado, BioFrontiers Institute, Boulder, USA (GRID:grid.266190.a) (ISNI:0000 0000 9621 4564)
8 University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X); Children’s Hospital Colorado, Center for Cancer and Blood Disorders, Aurora, USA (GRID:grid.413957.d) (ISNI:0000 0001 0690 7621)




